Translating MRD Success in Hematologic Cancers to Solid Tumors to Expand MRD Impact & Accelerate Clinical Trials
Time: 2:30 pm
day: Conference Day 1
Details:
- Exploring the role of minimal residual disease (MRD) in enhancing treatment strategies for hematologic cancers
- Leveraging MRD insights to optimize personalized therapies, improving patient outcomes and reducing relapse risks
- Discussing cutting-edge approaches to MRD detection and their impact on clinical decision-making in hematologic cancer management
Hematology
